Pemafibrate (K-877) is a novel selective PPARα modulator that improves dyslipidemia, plasma transaminase level, and the pathological condition of NASH in animal trials (Honda et al., 2017). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.